ViralClear partners with CDMO on potential COVID-19 treatment Merimepodib

ViralClear Pharmaceuticals has partnered with Albany Molecular Research Inc (AMRI) on the manufacture of Merimepodib API either as a stand-alone treatment or in combination with other antiviral agents or immune modulator

BioSig Technologies' subsidiary ViralClear Pharmaceuticals, supported by global CDMO Albany Molecular Research, is undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19. It is being investigated either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.

"As part of our ongoing development and commercialisation strategy we are delighted to be working with AMRI as our second US-based active pharmaceutical ingredient (API) supplier. The rapid transfer, scale-up, and validation of merimepodib API manufacture is key to our future supply chain and commercialisation strategy," explained Steve King, Chief Operating Officer of ViralClear. "ViralClear is committed to using US-based CDMOs for the development and commercialisation of merimepodib."

"AMRI is proud to partner with ViralClear in this vital effort of seeking a potential treatment for COVID-19," said Christopher Conway, President of AMRI. "Our team is committed to applying the expertise and experience we're renowned for to help combat this complex global health challenge."

Companies